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Background: The simian parasite Plasmodium knowlesi is recognized as a common cause of severe and fatal
human malaria in Sabah, Malaysia, but is morphologically indistinguishable from and still commonly reported as
Plasmodium malariae, despite the paucity of this species in Sabah. Since December 2008 Sabah Department of
Health has recommended intravenous artesunate and referral to a general hospital for all severe malaria cases of
any species. This paper reviews all malaria deaths in Sabah subsequent to the introduction of these measures.
Reporting of malaria deaths in Malaysia is mandatory.
Methods: Details of reported malaria deaths during 2010-2011 were reviewed to determine the proportion of each
Plasmodium species. Demographics, clinical presentations and management of severe malaria caused by each
species were compared.
Results: Fourteen malaria deaths were reported, comprising seven Plasmodium falciparum, six P. knowlesi and one
Plasmodium vivax (all PCR-confirmed). Of the six P. knowlesi deaths, five were attributable to knowlesi malaria and
one was attributable to P. knowlesi-associated enterobacter sepsis. Patients with directly attributable P. knowlesi
deaths (N = 5) were older than those with P. falciparum (median age 51 [IQR 50-65] vs 22 [IQR 9-55] years, p = 0.06).
Complications in fatal P. knowlesi included respiratory distress (N = 5, 100%), hypotension (N = 4, 80%), and renal
failure (N = 4, 80%). All patients with P. knowlesi were reported as P. malariae by microscopy. Only two of five
patients with severe knowlesi malaria on presentation received immediate parenteral anti-malarial treatment. The
patient with P. vivax-associated severe illness did not receive parenteral treatment. In contrast six of seven patients
with severe falciparum malaria received immediate parenteral treatment.
Conclusion: Plasmodium knowlesi was responsible, either directly or through gram-negative bacteraemia, for almost
half of malaria deaths in Sabah. Patients with severe non-falciparum malaria were less likely to receive immediate
parenteral therapy. This highlights the need in Sabah for microscopically diagnosed P. malariae to be reported as
P. knowlesi to improve recognition and management of this potentially fatal species. Clinicians need to be better
informed of the potential for severe and fatal malaria from non-falciparum species, and the need to treat all severe
malaria with immediate intravenous artesunate.
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The simian parasite Plasmodium knowlesi is commonly
misdiagnosed as Plasmodium malariae by microscopy
due to its near-identical appearance. However, in contrast
to the relatively benign clinical course of P. malariae,
P. knowlesi is now recognized as a common cause of se-
vere and fatal human malaria in Malaysian Borneo [1].
Cases have also been reported in West Malaysia [2] and
nearly all countries in Southeast Asia [3-10]. In Borneo,
P. knowlesi mono-infection accounted for 64% of malaria
admissions in Kapit, Sarawak [11], and 78% of malaria
admissions in Kudat, Sabah [12]. Severe disease has been
reported from Sarawak [1,11], Sabah [13,14], and West
Malaysia [2], including 13 fatal cases [1,11,13,14]. In a
retrospective study conducted from December 2007 to
November 2009 at Queen Elizabeth Hospital (QEH), a ter-
tiary referral hospital in Sabah, 22/56 (39%) patients ad-
mitted with PCR-confirmed knowlesi malaria had severe
disease by WHO criteria, and six (27%) died [14].
The 24-hour replication cycle of P. knowlesi may be
associated with rapid increases in parasitaemia and con-
sequent complications, and hence prompt diagnosis and
initiation of effective treatment is essential. The optimal
treatment however has not been determined. While
chloroquine was shown to be effective for uncompli-
cated knowlesi malaria in Kapit [15], the retrospective
study at QEH found faster parasite clearance times
with an oral artemisinin combination therapy (ACT),
artemether-lumefantrine [14]. Among patients with severe
knowlesi malaria, parasite clearance times were faster with
intravenous artesunate than with intravenous quinine, and
fewer patients who received artesunate died [14].
In Sabah, intravenous artesunate has been the recom-
mended treatment for severe malaria from any species
since December 2008. In addition, referral to a general
hospital is advised for patients with symptoms or signs
suggestive of severe disease. Despite these measures, 14
deaths from malaria were reported in Sabah during
2010-2011. In this study the case notes of all these
patients were reviewed to determine the Plasmodium
species causing fatal malaria in Sabah, and to identify
any notable differences in demographics, clinical features
and management of fatal malaria caused by the different
species.
Methods
Setting
The north-eastern Malaysian state of Sabah has an area
of 73,600 km2 and a population of 3.2 million [16]. Sit-
uated between 4° and 7° above the equator, Sabah has a
mostly tropical climate, with high humidity and rainfall
throughout the year and temperatures of 25-35°C. Ma-
laria incidence is estimated at 0.78/1000 persons/year
[17]. Sabah’s government health system comprises onetertiary-referral hospital offering specialist and sub-
specialist care, three general hospitals offering specialist
care, 18 district hospitals, 77 health clinics and 189 rural
clinics.
Case series
All deaths due to malaria in Sabah must be reported to
the Sabah Ministry of Health where they are reviewed.
Details of reported malaria deaths during 2010-2011
were obtained from the Sabah Department of Health.
Approval to review the case notes of fatal malaria cases
was obtained from the Medical Research sub-Committee
of the Malaysian Ministry of Health and the Health
Research Ethics Committee of Menzies School of Health
Research. Case notes were retrieved from district hospitals
and reviewed for clinical details, laboratory results and
cause of death.
Blood slides for malaria parasites were reported accor-
ding to a scale of 1+ to 4+ (1 + = 1-10 parasites/100 high
power microscopy fields [HPMFs] or 4-40 parasites/μL,
2 + = 11-100 parasites/100 HPMFs or 41-400 para-
sites/μL, 3 + = 1-10 parasites/HPMF or 401-4,000
parasites/μL, and 4+ = >10 parasites/HPMF or >4,000
parasites/μL). PCR was performed by the Sabah State
Reference Laboratory by methods previously published
[1,18]. The diagnosis of all fatal malaria cases was con-
firmed by PCR. Laboratory investigations and clinical
details are listed in Table 1.
Results
Fourteen deaths were reported during 2010-2011, in-
cluding five due to P. knowlesi mono-infection, one
P. knowlesi-associated fatality in which gram-negative
septic shock was thought to be the primary cause of
death, one death associated with P. vivax and seven
from P. falciparum.
Cases 1-5: fatal cases primarily attributed to PCR-
confirmed plasmodium knowlesi monoinfection
Case one
A 71-year-old man with a history of hypertension and
chronic obstructive pulmonary disease presented to
a district hospital with a seven-day history of fever
and dyspnoea, and reduced conscious state just prior
to presentation. His Glasgow Coma Score (GCS) was
recorded on arrival by a paramedic as 3/15 and shortly
afterwards as 10/15; his blood pressure was 75/49 mmHg
and his oxygen saturation was 75% on room air. Chest
auscultation noted prolonged expiratory phase but
no crackles or wheeze. Blood film was reported as
Plasmodium falciparum/P. malariae “3+”, and renal
failure was present. Chest radiograph showed no infil-
trates, and arterial blood gas was not performed. He was
commenced on intravenous fluids and quinine in addition
Table 1 Demographic, clinical and laboratory features of reported Plasmodium knowlesi deaths, on admission
Details Case 1 Case 2 Case 3 Case 4 Case 5 P. knowlesi-associated
gram-negative septic
shock
Age, years 71 65 51 50 49 36
Sex Male Male Male Male Female Female
Time to death, hours 1 75 16 56 63 84
Blood pressure, mmHg 75/49 117/73 70/40 83/51 112/51 131/87
Heart rate per minute 127 58 110 89 113 110
Oxygen saturation on
room air, %
75 92 90 60 88 85
PaO2:FiO2 ratio NA NA 66 115 91 NA
Axillary temperature, °C 39.4 36.8 37.6 37.5 36.7 37.8
Haemoglobin, g/dL (females
12.0-16.0, males 13.5-17.5)
14.9 14.6 9.4 10.9 12.6 11.1
WBC count, x 103 cells/μL
(4.5-11)
10.8 4.8 6.8 7.81 12.1 7.8
Platelet count, x 103 cells/μL
(150-450)
88 58 8 3 32 53
Serum creatinine, μmol/L
(63-133)
1451 NA 578 330 283 NA
Serum urea, mmol/L (1.0–8.3) 81.5 6.1 44 38.5 25 10.8
Total serum bilirubin, μmol/L
(<17)
NA NA 146 74 25 NA
Serum aspartate
aminotransferase, U/L (<37)
42 NA 53 NA 39 NA
Serum alanine aminotransferase
concentration, U/L (<40)
NA NA 28 49 20 NA
Serum albumin, g/L (35-60) NA NA 23 19 28 NA
Serum bicarbonate, mmol/L
(18-23)
NA NA 14 16.2 14 6.5
Serum lactate mmol/L (0.5-2.2) NA NA 6.4 6.8 NA NA
Blood cultures negative Not done negative negative Not done Enterobacter cloacae
Initial microscopic diagnosis P. falciparum”3+”
P. malariae “4+”
P. malariae “3+” P. malariae “4+” P. vivax “4+” P. malariae “4+” P. malariae “1+”
PCR result* P. knowlesi P. knowlesi P. knowlesi P. knowlesi P. knowlesi P. knowlesi
Initial therapy received IV quinine/oral
chloroquine,
primaquine and
doxycycline
Oral chloroquine IV artesunate Oral chloroquine
and primaquine
Oral chloroquine
and primaquine
Oral sulfadoxine/
pyrimethamine
and primaquine
NOTE. Laboratory reference ranges are given in parentheses.
NA, not available; IV, intravenous.
*Blood samples used for PCR-confirmation were taken on the day of hospital admission for cases 1, 3 and 5; day 2 for case 2; day 3 for case 4, and day 1 for case 6.
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gen saturation and blood pressure continued to deterio-
rate and he suffered a cardiac arrest 40 minutes after
presentation. PCR confirmed P. knowlesi mono-infection.
Case two
A 65-year-old man with a history of type 2 diabetes and
hypertension presented to a district hospital with a two-
day history of fever, lethargy, myalgia and retro-orbital
pain. On examination he was alert and orientated buthypoxic with an oxygen saturation of 92% on room air.
Initial blood film was reported as negative for malaria
parasites, and the patient was given a provisional diagno-
sis of dengue fever and commenced on intravenous
fluids. On day 2 a repeat blood film was reported as
P. malariae “3+” and oral chloroquine was started. The
following day the patient was noted to be tachypnoeic
and hypoxic (oxygen saturation 85% on room air), and
chest radiograph showed diffuse infiltrates. Emergency in-
tubation was performed however cardiac arrest occurred
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vere malaria with acute respiratory distress syndrome.
Case three
A 51-year-old man with no known medical history pre-
sented to a clinic with a four-day history of fever, rigours,
myalgia and arthralgia. On examination he was drowsy,
jaundiced, hypotensive (blood pressure 70/40 mmHg),
tachycardic (heart rate 110 beats/minute) and hypoxic
(oxygen saturation 90% on room air). Hepatomegaly was
noted on abdominal examination. Blood film was reported
as P. malariae “4+”, and he had renal failure with a crea-
tinine of 578 μmol/L. Chest radiograph revealed patchy
consolidation in both lung fields. He was commenced on
intravenous fluids, oxygen supplementation, inotropic
support, intravenous antibiotics and intravenous artesu-
nate, and transferred to a general hospital, where he was
intubated and ventilated and commenced on haemodialy-
sis. He died the following day from acute respiratory dis-
tress syndrome. Blood cultures were negative.
Case four
A 50-year-old man with no known medical history pre-
sented to a district hospital with a seven-day history of
fever and rigours and a three-day history of cough. On
examination he was alert and orientated but hypotensive
(blood pressure 83/51 mmHg) and hypoxic (oxygen sat-
uration 70% on 10 L oxygen via high flow mask), and
wheeze was heard on chest auscultation. Blood film was
reported as Plasmodium vivax “4+”. The patient was
commenced on intravenous fluids, antibiotics and oral
chloroquine, and transferred to a general hospital, where
he was intubated and ventilated, and commenced on ino-
tropic support. Chest radiograph showed diffuse infiltrates.
The patient had renal failure (creatinine 330 μmol/L) and
severe thrombocytopenia (3 x 103 platelets/μL) although
no bleeding complications were noted. Haemodialysis was
commenced and platelet transfusion given. On day 3 a re-
peat blood film was reported as P. malariae “4+”. Intra-
venous artesunate was commenced, however the patient
remained on maximum inotropic and ventilator support,
and further haemodialysis was temporarily unavailable. He
died nine hours later with multiple organ failure. Cause
of death was reported as severe malaria. Blood cultures
and dengue serology were negative, and PCR performed
on a blood sample taken on day 3 confirmed P. knowlesi
monoinfection.
Case five
A 49-year-old woman with no known medical illness
presented to a district hospital with a four-day history of
fever, cough and dyspnoea. On examination she was ta-
chypnoeic and hypoxic (oxygen saturation on room air
88%) and wheeze was heard on chest auscultation. Bloodfilm was reported as P. malariae “4+”, and renal failure
was present (creatinine 283 μmol/L). Bronchodilators,
intravenous antibiotics, oral chloroquine and primaquine
were commenced in addition to inotropic support and
transfer to a tertiary hospital. Chest radiograph on ar-
rival revealed bilateral lower zone infiltrates, and the pa-
tient was intubated and ventilated however developed
refractory hypotension and died the following morning.
Cause of death was stated as septic shock, although
blood cultures were not performed.
Case 6: fatality attributed to Plasmodium knowlesi-
associated gram-negative sepsis
A 36-year-old woman with no known medical illness pre-
sented to a district hospital with a seven-day history of
fever, cough and myalgia. Examination was unremarkable
and no features of severe malaria were evident. Blood film
was reported as P. malariae “1+” and she was treated with
oral sulphadoxine/pyrimethamine (SP) and primaquine.
On day 3, she was aparasitaemic, but had become ta-
chypnoeic (respiratory rate 44 breaths/minute), hypoxic
(oxygen saturation 85% on room air) and hypotensive, and
widespread wheeze was heard on chest auscultation. Chest
radiograph showed no infiltrates and arterial blood gas
revealed metabolic acidosis (PaO2 110 mmHg, pH=7.21,
bicarbonate 6.5 mmol/L). She was commenced on
bronchodilators, intravenous ceftriaxone and inotropic
support and transferred to a tertiary hospital where she
was intubated and ventilated and given intravenous arte-
sunate. Further investigation results at the tertiary hospital
included haemoglobin 8.0 g/dL, platelets 65 x 103/μL,
white cell count 6.6 x 103/mL, creatinine 149 μmol/L and
aspartate aminotransferase 795 U/L. Following admission
the patient’s blood pressure deteriorated further and she
developed a tachyarrthymia. Cardioversion was unsuccess-
ful and the patient died from cardiac arrest four hours
after arrival. Cause of death was reported as severe ma-
laria, however on review, blood cultures taken on admis-
sion to the district hospital were noted to be positive for
Enterobacter cloacae (reported as sensitive to ceftriaxone),
untreated until progression to septic shock. Repeat cul-
tures taken after antibiotics at the referral hospital were
negative.
Case 7: fatality associated with vivax malaria
An 85 year-old-woman presented to a district hospital
with fever, rigours and abdominal pain. On examination
she was pale, tachypnoeic and hypoxic with oxygen sa-
turation of 88% on room air. Her blood pressure was
137/88 mmHg, and chest auscultation was clear. No ar-
terial blood was available. On abdominal examination a
tender pulsating mass was noted, and bedside ultra-
sound confirmed a 7.6 cm x 5.6 cm abdominal mass
with minimal free fluid. No computed tomography scan
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was made, and after discussion with family, conservative
management was planned. Blood investigations revea-
led anaemia (haemoglobin 8.8 g/dL), thrombocytopenia
(platelets 15 x 103/μL) and acute kidney injury (creatinine
149 μmol/L, urea 28 mmol/L). Blood film was reported as
P. malariae “4+”, and oral chloroquine was commenced.
Her condition deteriorated with increasing oxygen
requirements and on day 3 her blood pressure became un-
recordable. The cause of death was reported as dissecting
aortic aneurysm. PCR identified P. vivax mono-infection.
Cases 8-14: fatal falciparum malaria
The falciparum deaths comprised three children (aged
eight to 11 years) and four adults (aged 22–60 years). All
the children and two adults were Filipino. All met the
WHO criteria for severe malaria [19] on presentation,
with severity criteria including jaundice (N= 5) renal
failure (N = 4), respiratory distress (N = 4), anaemia
(N= 4), hypotension (N= 3) and cerebral malaria (N = 1).
One patient died without receiving anti-malarial treat-
ment due to a delayed diagnosis, but all others were
given intravenous quinine (N= 3) or artesunate (N = 3)
within two hours of malaria diagnosis. Three patients
were intubated and ventilated, three received inotropes
and two were dialyzed. Four patients died within one
day of presentation while three died at days 2-5. Blood
cultures in one child were positive for Enterobacter
aerogenes.
Discussion
This case series highlights the misdiagnosis of severe
knowlesi malaria due to continued reporting of P. knowlesi
as P. malariae. It also highlights the lack of recognition of
non-falciparum Plasmodium species as potential causes of
severe and fatal malaria, and the fatal consequences of ini-
tial oral therapy for severe malaria of any species, particu-
larly P. knowlesi.
In this series patients with deaths directly attributable to
P. knowlesi were older than those with fatal P. falciparum
(median age 51 [IQR 50-65] vs 22 [IQR 9-55] years,
p = 0.06). The older age group affected, and the complica-
tions experienced by the fatal knowlesi malaria patients,
are consistent with those already reported [1,11,14].
In particular, respiratory distress (oxygen saturation <94%
and respiratory rate >30 breaths/minute) occurs common-
ly in knowlesi malaria [11,14], and was present in all
patients. Diffuse infiltrates were seen on chest radiograph
in four patients, and three of these patients met the cri-
teria for acute respiratory distress syndrome (ratio of the
partial pressure of oxygen to the fraction of inspired oxy-
gen [PaO2:FiO2] <200). All patients required ventilatory
support, and respiratory failure contributed directly to
cause of death in at least four patients. Renal failure hasbeen reported to occur in 30–55% of patients with severe
knowlesi malaria [11,14], and occurred in four of five
(80%) patients in this series.
Hypotension is also a common complication of severe
knowlesi malaria, and occurred in four of five (80%)
patients with deaths directly attributable to P. knowlesi.
Pre-antibiotic blood cultures were taken in three of these
patients and were all negative. Relatively low rates of
clinically significant bacteraemia have been reported pre-
viously in severe knowlesi malaria [14], suggesting that
bacteraemia is unlikely to account for hypotension in
most patients with P. knowlesi. Nevertheless, one patient
in this series who presented with uncomplicated know-
lesi malaria had Enterobacter cloacae bacteraemia on ad-
mission, with bacterial septic shock the likely cause of
death. This species was also identified in the only other
report of clinically significant bacteraemia in a patient
with severe knowlesi malaria [14]. Gram-negative bacte-
raemia is a well-recognized complication of severe fal-
ciparum malaria in children, and is associated with
increased mortality [20-25]. The proposed mechanisms
of the association between falciparum malaria and
bacteraemia include an increased risk of non-typhoidal
Salmonella due to malaria-induced haemolysis and neu-
trophil dysfunction [26], impaired macrophage function
due to haemozoin deposition in monocytes [27-29], and
nitric oxide quenching [30]. Bacterial translocation into
the blood stream has also been hypothesized as a result
of microvascular sequestration of P. falciparum in gut
mucosa, and parasite accumulation in multiple organs
was demonstrated in the single P. knowlesi autopsy report.
Further studies are required to investigate mechanisms of
bacteraemia in P. knowlesi infection.
Coma has not been reported to occur in knowlesi ma-
laria, despite the only autopsy report demonstrating cere-
bral accumulation of parasitized red blood cells [13]. One
patient in this study was reported to have had reduced
consciousness and hypotension just prior to death. His
altered conscious state however likely reflected his agonal
state and is not consistent with cerebral malaria.
In contrast to other human malarias, P. knowlesi has
a 24-hour replication cycle, which can lead to rapid
increases in parasitaemia. Diagnosis of this malaria spe-
cies is therefore critical in order that its potential to
cause severe disease is recognized, appropriate treatment
instituted without delay, and further complications and
fatalities avoided. In this series, no patient was correctly
diagnosed with P. knowlesi. Rather, all received a diagno-
sis of P. malariae, despite a very low incidence of this
species in Sabah, with P. malariae detected by nested
PCR in only 2 of 318 (0.6%) microscopy-diagnosed
P. malariae cases referred to the Sabah State Public
Health Laboratory in 2009 [31]. On thick film micros-
copy, P. knowlesi is indistinguishable from P. malariae.
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between the late stages of P. knowlesi and P. malariae on
thin film microscopy, these are not consistent and cannot
be relied upon in clinical practice [32]. P. malariae causes
a relatively benign acute illness, with low parasitaemia and
only very rare reports of acutely severe malaria [33,34].
Current textbook descriptions and treatment guidelines re-
flect this. As has been previously recommended [1], this
case series highlights the need for blood films positive for
malaria parasites resembling P. malariae to be reported as
P. knowlesi in Sabah, in order to direct clinicians in the re-
cognition and management of this potentially fatal species.
Moreover, this case series illustrates the importance of
a unified treatment policy for all patients with severe
malaria, regardless of species [35]. Although the optimal
treatment of knowlesi malaria has not been determined,
severe disease should be treated as for severe falciparum
malaria, including immediate institution of parenteral
artesunate. Plasmodium knowlesi is also sometimes mis-
diagnosed as P. vivax (as occurred initially in one patient
in this series) and P. vivax can also cause severe and
fatal disease [36,37]. For both these reasons, P. vivax
should also be treated with intravenous artesunate if
signs of severity are present, particularly as oral chloro-
quine may be poorly absorbed in acutely unwell patients
and chloroquine-resistant P. vivax is increasingly pre-
valent in Southeast Asia [38]. This unified treatment
strategy for severe malaria from all species, including
P. knowlesi, has been Sabah state policy since 2008 and
has been adopted in the latest WHO severe malaria
management guidelines [35]. Despite this policy, in this
case series only two of five patients with knowlesi ma-
laria who met severity criteria on admission received im-
mediate parenteral treatment, with the others receiving
oral chloroquine. Similarly, the one patient with vivax
malaria, who also met severity criteria on admission, was
treated only with oral chloroquine. In contrast, six of
seven patients with severe falciparum malaria received
parenteral treatment within two hours of diagnosis
(p = 0.07 for fatal P. falciparum vs non-falciparum; Yates
corrected Chi2). These findings suggest a lack of recog-
nition of the potential of the non-falciparum malarias to
cause severe disease and the need for treatment with
intravenous artesunate for all severe malaria patients.
This study had several limitations, the major one being
its retrospective design resulting in unavoidably incom-
plete laboratory and clinical data. Blood culture results
were not available for two patients, and for these pa-
tients bacterial sepsis cannot be excluded as contributing
to poor outcome. Lack of accurate parasite density counts
also made assessment of parasite burden difficult. Post-
mortem examination was not performed for any patient,
preventing detailed description of the pathogenic mecha-
nisms of severe malaria and death.Conclusion
Plasmodium knowlesi is a common cause of malaria in
Sabah, and in this series was responsible, either directly
or through bacteraemia, for almost half of malaria
deaths throughout the state. These results highlight the
importance of accurate reporting of P. knowlesi to im-
prove recognition and management of this species. Cli-
nicians need to be better informed of the potential for
severe and fatal malaria from non-falciparum species, es-
pecially P. knowlesi, and the need to treat all severe ma-
laria with immediate intravenous artesunate regardless
of species.
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